Neratinib is an oral, irreversible pan-inhibitor of HER family which was investigated in a phase II trial of the Translational Breast Cancer Research Consortium (TBCRC) enrolling pre-treated, symptomatic HER2-positive BM. This evidence concerns the gene ERBB2 and breast cancer.